During the last session, Fate Therapeutics Inc (NASDAQ:FATE)’s traded shares were 1.18 million, with the beta value of the company hitting 1.68. At the end of the trading day, the stock’s price was $6.92, reflecting an intraday loss of -0.72% or -$0.05. The 52-week high for the FATE share is $8.83, that puts it down -27.6 from that peak though still a striking 76.45% gain since the share price plummeted to a 52-week low of $1.63. The company’s market capitalization is $686.74M, and the average intraday trading volume over the past 10 days was 2.13 million shares, and the average trade volume was 2.92 million shares over the past three months.
Fate Therapeutics Inc (NASDAQ:FATE) trade information
Fate Therapeutics Inc (FATE) registered a -0.72% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -0.72% in intraday trading to $6.92, hitting a weekly high. The stock’s 5-day price performance is -5.72%, and it has moved by -13.28% in 30 days. Based on these gigs, the overall price performance for the year is 25.14%. The short interest in Fate Therapeutics Inc (NASDAQ:FATE) is 13.16 million shares and it means that shorts have 4.7 day(s) to cover.
Fate Therapeutics Inc (FATE) estimates and forecasts
Statistics show that Fate Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Fate Therapeutics Inc (FATE) shares have gone up 293.18% during the last six months, with a year-to-date growth rate less than the industry average at -18.29% against 13.50. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -157.90% this quarter and then jump 9.30% in the quarter after that. In the rating firms’ projections, revenue will decrease -93.60% compared to the previous financial year.
Revenue for the current quarter is expected to be $1.11 million as predicted by 14 analyst(s). Meanwhile, a consensus of 14 analyst(s) estimates revenue growth to $1.13 million by the end of Jun 2024. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $58.98 million and $5.53 million respectively. In this case, analysts expect current quarter sales to shrink by -98.10% and then drop by -79.60% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -6.65%. While earnings are projected to return -17.51% in 2024.
FATE Dividends
Fate Therapeutics Inc is due to release its next quarterly earnings between May 01 and May 06. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Fate Therapeutics Inc (NASDAQ:FATE)’s Major holders
Fate Therapeutics Inc insiders own 1.47% of total outstanding shares while institutional holders control 91.88%, with the float percentage being 93.25%. Redmile Group, LLC is the largest shareholder of the company, while 226 institutions own stock in it. As of Jun 29, 2023, the company held over 13.12 million shares (or 13.32% of all shares), a total value of $62.47 million in shares.
The next largest institutional holding, with 11.98 million shares, is of Blackrock Inc.’s that is approximately 12.15% of outstanding shares. At the market price on Jun 29, 2023, these shares were valued at $57.02 million.
Also, the Mutual Funds coming in first place with the largest holdings of Fate Therapeutics Inc (FATE) shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. Data provided on Aug 30, 2023 indicates that SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF owns about 8.05 million shares. This amounts to just over 8.16 percent of the company’s overall shares, with a $20.2 million market value. The same data shows that the other fund manager holds slightly less at 2.56 million, or about 2.60% of the stock, which is worth about $12.2 million.
